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A female infant, the product ofan uncomplicated full-term pregnancy
in a 26-year-old primipara. was admitted to a local hospital at 26 days of
age because of vomiting. Her weight stabilized at 3.0 kg and a relatively
hyperosinolar formula, Baker's formula5, was prescribed. The baby
continued to vomit, however, and the formula was changed to one
containing evaporated milk. At 2.5 months of age the baby was still
feeding poorly; she was found to be anemic and was given three iron
and vitamin injections. The formula was changed to Enfamil and iron,
which she did not tolerate well.
At age 3 months, I week, she was admitted to another local hospital
because of vomiting and diarrhea. She was severely anemic, acidotic,
and dehydrated, and she was treated with intravenous fluids and
antibiotics. The diarrhea abated after 2 or 3 days, and intravenous
therapy was discontinued after 10 days.
Approximately 12 days after admission, the patient went into shock;
the morning before, serum total carbon dioxide content had been 3.7
mEq/liter. She was treated with bicarbonate and intravenous fluids. In
response to the administration of vasopressin, the urinary specific
gravity failed to increase, and nephrogenic diabetes insipidus" was
diagnosed. A Hickey-Hare test also failed to produce an antidiuresis.
At 4 months of age, hydrochlorothiazide, 5 mg/kg per day, and a low-
sodium diet were prescribed for treatment of nephrogenic diabetes
insipidus. Ten days later she was transferred to the University of
California San Francisco (UCSF) Hospital because the polyuria failed
to respond to therapy.
Physical examination at the time of admission revealed a cachectic,
dwarfed, mildly dehydrated 4-month-old female infant in no acute
distress. Her weight was 3.02 kg (—6 SD), her height was 50 cm (—5
SD), and her head circumference was 37 cm (—2 SD). The mucous
membranes were moist, the skin was doughy feeling, and the fontanelle
was slightly sunken. Deep tendon reflexes were 2+ and equal bilateral-
ly.
Laboratory studies on admission revealed a serum sodium of 141
mEq/liter: potassium, 2.0 mEq/liter; chloride, 77 mEq/liter; and total
carbon dioxide content, 46 mEq/liter. On the following day, serum
sodium was 131 mEq/liter: potassium. 1.5 mEq/liter; chloride. 80 mEq/
liter; total carbon dioxide content, 48 mEq/liter; and arterial pH. .7l.
Hydrochlorothiazide was discontinued and the child was treated with
potassium chloride. Over the following 2 days, her total carbon dioxide
content fell to 34 mEq/liter. Serum phosphorus and serum calcium were
normal, as were urinary excretion of phosphorus, glucose, and amino
acids. Urine tests for phenylketonuria were negative. An eye examina-
tion revealed no cystine crystals. Radiologic examination of the bones
showed only osteopenia. Urinary cultures on three occasions showed
no growth.
After 6 days of potassium chloride and a low-salt diet, her total
carbon dioxide content had fallen from 34 to 12 mEq/liter, serum
potassium was 3.6 mEq/liter, and the urinary pH was 7.2. A presump-
tive diagnosis of type-I renal tubular acidosis was made, and treatment
with potassium bicarbonate, 2 mEq/kg body weight per day, was
instituted. After 2 days, her total carbon dioxide content rose to 19
mEq/liter. To maintain the total plasma carbon dioxide content at
approximately 23 to 25 mEq/liter and the serum potassium at 3.8 to 4.8
mEq/liter, the following dosage regimen was required: potassium
bicarbonate, 4 mEq/kg/day; sodium bicarbonate, 8 mEq/kg/day; and a
moderately low sodium chloride diet of SMA 26, which provided a
chloride intake of I to 3 mEq/kg/day and a relatively low osmolar load.
After 2 weeks of potassium and alkali replacement therapy and sus-
tained normokalemia. the patient underwent urinary concentration lests
with 2 units of vasopressin (Pitressin) administered intramuscularly.
Urinary osmolality prior to administration of Pitressin5 was 177 mOsm/
kg and fell to 122 mOsm/kg afterward. Urinary osmolalities of 70
mOsm/kg or less were observed repeatedly when free access to ssater
was allowed. It was concluded that the child had no difficulty in urinary
dilution, but at the time her urinary concentrating capacity was restrict-
ed. The pattern of bicarbonate excretion was evaluated on two occa-
sions during sodium bicarbonate infusion over a plasma bicarbonate
range of 15 to 30 mEq/liter. Identical excretion patterns were obtained
on both occasions and demonstrated a 10% to l5% urinary leak of the
filtered load over the entire range of plasma bicarbonate concentration.
At 6 months of age, ingestion of a normal diet including meat for one
week resulted in the reappearance of dehydration; consequently a meat-
free, low-solute diet was reinstituted. During the rest of the hospitaliza-
tion, large quantities of alkali were given, and the infant hsd a
remarkable growth spurt; over a 10-week period (from 4.0 to 6.5 months
of age) her height increased from 50 to 56cm, and her weight rose from
3.0 to 3.85g. She was discharged with three diagnoses: (1) renal tubular
acidosis, infantile renal bicarbonate wasting, type I; (2) polyuria of
chronic potassium depletion; and (3) severe failure to thrive.
The child has been maintained on large doses of alkali, 8 to 12 mEq/
kg/day (50% to 80% as the potassium salt of bicarbonate). She has had
no significant difficulty with polyuria. At her present age of l2 years,
she is 57" tall. By radiologic examination she remains free of nephrccal-
cinosis.
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Discussion
DR. ELISABETH MCSHERRY (Associate Clinical Professor of
Pediatrics, University of Califrirnia San Francisco, Cali'ftir-
nia): I plan first to summarize the pathophysiology of renal
tubularacidosis (RTA) [1—28] and then apply this information to
the unusual manifestations of RTA in this patient. Later, I will
classify the major types of RTA into categories, including a new
schema for the five subtypes of type-4 RTA. I will conclude
with a summary of some of our recent experimental findings in
RTA. These include the effects of acidosis on (I) inhibition of
growth; (2) the release of human growth hormone; (3) collagen
metabolism; and (4) the urinary excretion of pseudoephedrine
(Sudafed®).
Normal renal acidification and its assessment
The proximal convoluted tubule reabsorbs the bulk of the
filtered bicarbonate and sodium [27, 28]. In the adult, approxi-
mately 85% of the filtered bicarbonate is reabsorbed by the
proximal convoluted tubule at normal plasma bicarbonate con-
centrations, compared to approximately 65% in the infant. 'l'he
remainder of the filtered bicarbonate normally is reabsorbed in
the distal tubule, in part by an aldosterone-dependent process.
In the collecting duct, the luminal fluid is essentially free of
bicarbonate and its pH is approximately 6.2. The filtrate is
acidified further in the collecting duct by the establishment of a
lumen-peritubular hydrogen ion gradient. Hydrogen ions are
excreted with two major buffers: ammonia, a freely diffusible
gas, is trapped in the lumen as ammonium ions; and phosphate
buffers are titrated to their hydrogen-rich form. Buffered phos-
phate makes up the major part of titratable acid in the urine.
Proximal bicarbonate reabsorption
Reabsorption of bicarbonate in the proximal tubule is
achieved by a hydrogen secretory process that is regulated by
several factors: carbonic anhydrase activity, extracellular vol-
ume, carbon dioxide tension, and body potassium stores. A fall
in extracellular volume or body potassium, or a rise in PCO2
increases proximal tubular reabsorption of bicarbonate; a rise in
extracellular volume or body potassium, or a fall in PCO2
inhibits proximal bicarbonate reabsorption. In certain circum-
stances, other factors such as parathyroid hormone, serum
calcium, and serum phosphorus also affect proximal tubular
bicarbonate reabsorption. For example, in normal persons,
acute infusions of parathyroid hormone can increase urinary
losses of bicarbonate; in patients with Fanconi's syndrome and
defective proximal bicarbonate reabsorption, inhibition of para-
thyroid hormone by an infusion of sufficient calcium to maintain
normocalcemia ameliorates the proximal acidification defect
[29].
One can indirectly assess acidification in the proximal tubule
by measuring urinary bicarbonate excretion when plasma bicar-
bonate is stable at a normal or slightly reduced level. Under
these conditions, if there is a proximal tubular defect, bicarbon-
ate escapes reabsorption and spills into the urine (see Fig. I): a
fractional bicarbonate excretion greater than 15% in the adult or
greater than 25% in the child suggests a defect in proximal
tubular acidification, In contrast, if there is an isolated distal
tubular defect, less bicarbonate escapes into the urine: in
patients with distal RTA, fractional bicarbonate excretion at a
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Fig. I. Schematic representation (f the nephron in normals (left) and
(rig/it) in patients wii/m nonazoternjc rype—2 RTA at various filtered loads
of bicarbonate. On the second panel from left: at normal plasma
bicarbonate and filtered loads, the RTA-proximal tubule spills unreab-
sorbed bicarbonate and overwhelms the distal tubule's capacity to
reabsorb bicarbonate so mild acidosis (third panel from left) occurs.
Then, the load to the proximal tubule is lower, and less bicarbonate is
spilled distally. On the right panel, during more profound acidosis the
filtered load of bicarbonate is so small that the proximal tubule's
capacity to reabsorb 85% of it is sufficient, and therefore the distal
tubule's capacity is no longer overwhelmed by a massive proximal
bicarbonate spill. Since the distal tubule now can completely reabsorb
its load(15% of that filtered), it presents an intraluminal fluid with a pH
of 6.2 to the collecting duct, so a normally low urinary pH is generated.
normal plasma bicarbonate concentration never exceeds 15% in
adults or 25% in infants.
Distal bicarbonate reabsorption and acidification
The distal nephron, especially the cortical collecting tubules,
reahsorbs sodium in part by an aldosterone-dependent process.
Secretion of hydrogen and potassium ions also may be under
direct, as well as indirect, aldosterone control. Thus, aldoster-
one deficiency or renal tubular resistance to aldosterone would
be expected to result in inappropriate urinary bicarbonate
excretion, at least at normal plasma bicarbonate concentra-
tions. In addition, hyperkalemia, consequent to the aldosterone
deficiency, also affects renal acidification by impairing the renal
synthesis of ammonia, thereby reducing net acid excretion in
the distal tubule and collecting duct [28J.
"Distalmost" tubular acidifying ability is assessed by the
measurement of pH, ammonia, and titratable acid during spon-
taneous acidosis or ammonium chloride-induced acidosis. If
urinary pH does not fall to or below 5.5, and if ammonia and
titratable acid excretion do not increase to at least 35 Eq/min/
1.73M2 and 25 pEq/min!1.73M2, respectively, defective acidifi-
cation by the distal collecting duct is probably present.
To summarize, normal renal acidification occurs if (I) the
proximal tubule reabsorhs an appropriate amount of filtered
bicarbonate; (2) sufficient aldosterone is available, and the
distal tubule responds to it; (3) the collecting tubule's intrinsic
capacity to secrete hydrogen ions against a steep gradient is
intact and is not overwhelmed by excessive amounts of bicar-
bonate that escape proximal reabsorption; (4) adequate
amounts of sodium and urinary buffer are available to maintain
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hydrogen ion secretion; and (5) ammoniagenesis is not im-
paired.
Clinical case discussion
Before discussing RTA in general, I would like to discuss the
infant presented today. The first notable finding in this patient
was failure to thrive. From the age of I month she was
hospitalized several times with an erroneous diagnosis of "milk
intolerance," and treatment consisted only of many formula
changes. More than 4 months passed before the diagnosis of
renal tubular acidosis was made. In retrospect, most of the
characteristic physical signs and symptoms of RTA were pres-
ent long before. These included: (I) stunted height and weight
( 2.5 SD below the mean for age- and sex-matched normals);
(2) proximal muscle wasting and muscle weakness; (3) listless-
ness; (4) anorexia, vomiting, constipation, and dehydration: (5)
gray pallor and superficial venospasm during phlebotomy; and
(6) polyuria. Although many of these physical findings also
occur in infants with nephrogenic diabetes insipidus, the bio-
chemical findings in this latter disorder are quite different. A
vasopressin test was found to be abnormal in this patient, but
careful examination of blood electrolytes, blood gases, and
urinary pH was not carried out. As a result, nephrogenie
diabetes insipidus was erroneously diagnosed and chlorothia-
zide was prescribed.
The patient was referred to UCSF after one week of thiazide
therapy. On admission she had an elevated plasma bicarbonate,
was severely alkalemic, and was approximately 5% to 10%
dehydrated. Chlorothiazide was discontinued and therapy with
potassium chloride was started. Within 6 days, the plasma
bicarbonate fell to 12 mEq/liter, the serum potassium was 3.6
mEq/liter, and the simultaneous urinary pH was 7.2; during this
period the child remained profoundly ill.
Renal tubular acidosis with renal bicarbonate wasting was
suspected during the patient's first week of hospitalization at
UCSF. Renal bicarbonate wasting is defined as a urinary
excretion of greater than 3 mEq of bicarbonate per kg body
weight per day at any time when the plasma bicarbonate level is
normal or below. I should add that although renal bicarbonate
wasting is rare in adults with type-I ("classic," "distal") RTA,
it is characteristic in infants and children with this disorder [12—
17, 20—22].
What were the clues that renal bicarbonate wasting was
present in this infant? First, the rapid onset of profound and
progressive acidosis in less than one week (as potassium was
replenished) strongly suggested renal bicarbonate wasting. In
patients with renal tubular acidosis and bicarbonate wasting.
acidosis occurs rapidly when alkali is withheld, and loading
with ammonium chloride rarely is required to make the diagno-
sis. Second, a urinary pH consistently greater than 7 despite
appreciable hypobicarbonatemia (bicarbonate, 12 mEq/liter),
suggested that abnormally large amounts of bicarbonate were
being excreted in the urine. Third, urinary bicarbonate wasting
was 3% to 10% of the filtered load, measured when the plasma
bicarbonate concentration was 12 mEq/liter.
Two additional clues suggested renal bicarbonate wasting
during the subsequent sustained correction of acidosis with
alkali therapy: (I) large amounts of alkali, 5 mEq/kg/day or
more, were required to sustain correction of acidosis; and (2) at
the same time, the urinary pH rose rapidly to 7.8 or higher.
This patient illustrates that in children with profound renal
bicarbonate wasting, ammonium chloride loading is unneces-
sary (and potentially harmful) because profound acidosis can
occur rapidly when alkali therapy is withheld. Alkali therapy
was given to match the estimated maintenance requirement of
10 mEq/kg/day in this patient. This requirement was estimated
assuming a value for endogenous acid production in growing
children of 2 to 3 mEq/kg/day and from the measured renal
bicarbonate wasting of 5 to 7 mEq/kg/day. Serum calcium,
phosphorus, and magnesium also were monitored carefully
during alkali therapy.
With sustained correction of acidosis, the infant grew at
threefold her prior rate, and for a few months her growth was
equivalent to a rate of 60 cm/year! Her color returned to a
healthy pink; anorexia, vomiting, and constipation disappeared;
and her muscle mass, tone, and strength improved. Within 6
months, she was of average size and seemed normal in all other
ways as well.
Classification of R TA
Renal tubular acidosis is a biochemical syndrome character-
ized by minimal or absent azotemia and hyperchloremic acido-
sis.
Type-I renal tubular acidosis ("classic," 'distal," "RTA-l ")
Prototypic type-I RTA is the only type of RTA in which
urinary pH is high at all times (usually > 6.2), even du:ring
severe metabolic acidosis [1—li]. Failure to thrive is the most
common presentation in infants and children [1—22]. In older
children, renal stones and nephrocalcinosis occur as well.
Type-I RTA presents as a metabolic emergency in less than
25% of patients; manifestations include acute hypokalemic
paralysis, metabolic coma, or shock and, in extreme instances,
death [22]. In infants and children with type-I RTA, minimal
urinary pH often exceeds 6.5, and bicarbonaturia persists even
during profound systemic acidosis. The magnitude and persis-
tence of the bicarbonaturia (3—12 mEq/kg/24 hours) can result in
life-threatening acidosis (bicarbonate  3 mEq/liter) if treat-
ment is not given [13—22]. The magnitude of the renal bicarbon-
ate wasting is the major determinant of the amount of alkali
therapy required to correct systemic acidosis in children with
type-I RTA; the alkali dose required is calculated, as described
above, by adding the measured urinary bicarbonate excretion to
the estimated endogenous production of nonvolatile acid (Table
I).
In contrast to the importance of renal bicarbonate wasting in
children, endogenous production of acid ( 1 mEq/kg/day) is
the major determinant of therapy in virtually all adults with
type-l RTA. Sebastian et al at UCSF, however, have studied 2
adults with hereditary type-I RTA with renal bicarbonate
wasting similar to that in children (unpublished observations).
In infants and children, type-I RTA usually is inherited as a
Mendelian dominant trait, sometimes occurring in association
with other diseases such as elliptocytosis and the Ehlers-Darilos
syndrome, but occasionally appearing spontaneously (Table 2).
In the past, stunted growth has been a characteristic finding in
infants and children with type-I RTA and chronic acidosis. But
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Table I. Determinants of alkali therapy in RTA
Magnitude of acid input
I. Normal net acid production
Adults: 0.5—1.5 mEq/kg/day
Children: 1—3 mEq/kg/day
2. Increased net acid production
Increased bone mineralization (with
rapid growth and/or remineralization)
Gastrointestinal losses of alkali
Magnitude of acid/alkali excreted
1. Urinary excretion of ammonium and titratable acid
2. Urinary loss of bicarbonate
Table 2. Causes of type-I RTA ("distal')
Isolated primary_defect
Mendelian dominant heredity
Spontaneous
Associated with other disorders
Autoimmune
Sjogren's syndrome
Lupoid hepatitis
Systemic lupus erythematosus
Genetically transmitted diseases
Sickle cell anemia
Elliptocytosis
Carbonic anhydrase-B deficiency
Ehlers—Danlos syndrome
Marf'an's syndrome
Other renal diseases
Renal transplantation
Obstructive uropathy
Pyelonephritis
Postrubella
Disorders causing riephrocalcinosis
Idiopathic hypercalciuria (genetic or sporadic)
Primary hyperparathyroidism
Medullary sponge kidney
Wilson's disease
Hyperthyroidism
Drug or toxin-induced nephropathy
Amphotericin B
Lithium
Cyclamates
Analgesics
we now know that ifacidosis is corrected for a sustained period,
such children can attain normal stature. In 1978, we reported
that 10 children with type-I RTA attained normal stature when
correction of acidosis was sustained by treatment with high-
dose alkali therapy (5—15 mEq/kg/day). The study included 6
children whose heights were more than 2.5 SD below the mean
for age- and sex-matched controls [12, 13, 20, 21]. It is
interesting that if acidosis is only partially corrected by using no
more than 3 mEq of bicarbonate/kg/day, nephrocalcinosis oc-
curs by the time the patient is 4 years of age [9, II, 15, 16, 20,
30]. In our experience, however, none of 7 children with type-I
RTA treated from infancy with high-dose alkali therapy has
developed nephrocalcinosis during a 10- to 20-year follow-up
period [20, 30]. Hence, conscientious maintenance of normal
plasma bicarbonate and serum potassium levels confers long-
term advantages on the child with type-l RTA.
Other benefits that accrue from adequate treatment of acido-
sis include resolution of hypokalemia, proximal muscle myopa-
Table 3. Causes of type-2 RTA ("proximal")
I. With Fanconi's syndrome
A. As inborn error of metabolism (Mendelian recessive)
Cystinosis HFI (receiving fructose)
Lowe's syndrome Galactosemia (receiving galactose
Tyrosinosis Pyruvate carboxylase deficiency
B. As metabolic consequence
Chronic hypocalcemia and secondary hyperparathyroidism
Sprue Nutritional vit. D deficiency (stage 3, 4)
Gut-bypass Vitamin D dependency syndromes
Drug or toxin-induced
Lead
Streptozotocin
Outdated tetracycline
Diacromone
Rubella syndrome
C. After renal injury
Medullary cystic disease
Nephrotic syndrome
Postrcnal transplant
Multiple myeloma
II. As isolated proximal tubule defect of bicarbonate reabsorption
Carbonic anhydrase deficiency
Secondary to drugs
Diamox
Sulfanilamide
Genetically transmitted (Russell)
Idiopathic (Donkerwolke)
Idiopathic
York-Yendt
Transient (infants)
thy, polyuria, and listlessness [22]. Sodium bicarbonate is the
preferred choice of alkali; it is inexpensive, easy to prepare, and
directly usable in the body without being metabolized by the
liver. For children less than 4 years old, alkali is formulated as a
1 mEq/ml solution: an 8-oz box of Arm and Hammer® baking
soda is dissolved in 2.88 liters of distilled water. The solution is
administered either undiluted or mixed with a small amount of
milk or formula. If alkali is mixed with certain dehydrated
"juice crystals," such as Tang®, alkali potency per mixed dose
appears to fall by at least 40% (unpublished observations). The
mechanism for this phenomenon has not been delineated.
Type-2 renal tubular acidosis ("proximal," "RTA-2")
Type-2 RTA is characterized by a defect in proximal bicar-
bonate reabsorption. Typically, manifestations of Fanconi's
syndrome coexist, including reduced proximal tubular reab-
sorption of amino acids, phosphate, calcium, glucose, urate,
lysozyme, light-chain immunoglobulins, and citrate. In chil-
dren, type-2 RTA leads to rickets, delayed bone maturation,
and stunted growth [22, 27, 28]. In untreated patients with type-
2 RTA, urinary pH is 6.0 or less; during sustained correction of
acidosis, urinary pH rises due to marked bicarbonaturia, which
often exceeds 15% to 20% of the filtered load. As discussed
earlier, this degree of bicarbonaturia indicates that an acidifica-
tion defect of the proximal nephron exists (see Fig. I).
Type-2 RTA with Fanconi's syndrome occurs as a permanent
condition in association with several disorders of Mendelian
recessive inheritance including cystinosis, Lowe's syndrome,
tyrosinosis, and fructose and galactose intolerances (when the
offending sugar is eaten). It also occurs with medullary cystic
disease and with idiopathic complete and partial Fanconi syn-
Subtype
Number Mechanism and designation
Aldosterone deficiency without intrinsic renal disease
I) Primary mineralocorticoid deficiency
(Addison's; congenital adrenal hyperplasia;
isolated hypoaldosteronism)
Aldosterone deficiency with chronic hyporeninemia
2) Primary hyporeninemic secondary hypoaldosteronism
of azotemic adults (diabetes, gout, pyelonephritis
interstitial ne huitw, nephrosclerosis)
3) Adolescent hyperkalemic syndrome ('!Cl-shunt)
Reduced tubular responsiveness to aldosterone
4) Pseudohypoaldosteronism
5) "Early childhood" type-4 RTA
a BP refers to blood pressure.
NI refers to normal.
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dromes. Type-2 RTA sometimes appears transiently after viral
or toxic renal injuries and with long-term vitamin D deficiency
(Table 3). One group has reported that type-2 RTA occurs as a
transient syndrome in infants and young children without
evidence of any other proximal tubular dysfunction [5]. In some
of these patients, fractional bicarbonate excretion was not
sufficiently high to ensure a defect of the proximal nephron
(i.e., <25%), and serum potassium concentrations were consis-
tently high during spontaneous acidosis. The possibility thus
exists that this transient infantile disorder, "pure proximal
type-2 RTA," may represent a variant of subtype 5 of type-4
RTA (see below).
In nonazotemic patients with type-2 RTA, maintenance of
normal levels of serum bicarbonate proves difficult even with
massive doses of alkali because of the equally massive hicar-
bonaturia. Despite alkali therapy, extracellular volume deple-
tion is common and, as a consequence, sustained secondary
hyperaldosteronism is characteristic 127, 28]. Potassium excre-
tion is increased by two phenomena: (I) increased aldosterone
stimulates distal potassium secretion; and (2) bicarbonate,
overflowing from the proximal tubule, acts as a poorly reab-
sorbable anion in the distal tubule, causing an obligate loss of
potassium. For these reasons, at least one-half of the alkali
usually required to sustain correction of acidosis (10 to 25 mEq/
kg/day) should be administered with potassium. In some pa-
tients, such large doses of alkali are poorly tolerated by the
gastrointestinal tract. Dietary salt restriction and chiorothiazide
therapy can be useful adjuncts in patients with severe renal
bicarbonate losses; within several days this regimen inhibits
renal bicarbonate excretion. Potassium supplements always are
required to sustain normokalemia in children with nonazotemic
type-2 RTA. Hypophosphatemia and rickets are effectively
treated with a combination of large doses of dihydrotachysterol
or vitamin D analogs [31, 32] and neutral isotonic sodium
phosphate solution [33, 34].
Type-3 renal tubular acidosis
In 1972 an allegedly new syndrome in infants was designated
type-3 RTA. It was characterized by a high urinary pH (> 6.9)
despite severe acidosis (implicating a defect in the distalmost
nephron) and by massive bicarbonaturia at all levels of plasma
bicarbonate concentration. As I discussed earlier, we now
know that all infants and children with type-i RTA have
considerable bicarbonaturia. In these patients, massive bicar-
bonate wasting subsides after adolescence or after rapid growth
spurts, but the distalmost acidification defect of classic type-I
RTA does not. Since type-3 RTA is simply the infant and
childhood manifestation of hereditary type-I RTA, most neph-
rologists classify it as the predictable pediatric variant of type-I
RTA rather than as a separate type.
Type-4 renal tubular acidosis
Type-4 RTA, the most common type of RTA in children and
adults, is characterized by hyperchloremic acidosis, hyperkale-
mia, and an acid urinary pH (during acidosis) [22, 35—55].
Currently, it is possible to distinguish five pathophysiologic
subtypes of type-4 RTA; such distinctions provide some useful
insights into the causes of the disorder (Table 4). Subtypes I
and 2 result from a primary hormonal deficiency of renin/
aldosterone and consequent understimulation of the aldoster-
one-sensitive sites in the distal convoluted tubule (Table 2);
subtypes 3 through 5 result from primary renal tubular disor-
ders.
Subtype 1, characterized by decreased urinary aldosterone
levels, increased plasma renin activity, and salt wasting, is
observed in association with Addison's disease, isolated pri-
mary hypoaldosteronism, or congenital adrenal hyperplasia.
The decrease in aldosterone secretion results in acidosis, hyper-
kalemia, and renal sodium chloride wasting.
Subtype 2, also known as hyporeninemic hypoaldosteronism.
and 'type-4 RTA in azotemic adults," is characterized by an
impairment of renal renin production caused by chronic intersti-
tial damage. As a consequence, aldosterone secretion falls and
the circulating aldosterone level is low. Hyperchloremic acido-
sis and hyperkalemia ensue but clinical salt wasting does not
occur, perhaps because of the concomitant azotemia.
Subtype 3 ("adolescent hyperkalemic syndrome." or "renal
chloride shunt") is characterized by hypertension, hypervole-
mia, and hypoaldosteronism [22, 35, 36, 48—531. In this cyn-
drome, for unknown reasons, excessive chloride reabsorption
Table 4. Pathophysiologic subtypes of type-4 RTA
Clinical finding
Plasma
renin
activity
Urinary Blood/
aldosterone plasma
1'
Salt
BPa volume wasting
1-
11
Not
11
Not NP' Low NI
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in the distal convoluted tubule apparently leads to hypervole-
mia and secondary suppression of aldosterone secretion [531.
Chlorothiazide corrected the hyperkalemia and acidosis in 7 of
13 pediatric patients with this syndrome [22, 38, 39, 48—53].
Dietary sodium chloride restriction also corrected the hyperka-
lemia and acidosis [22, 38, 39, 48—53].
Subtype 4 (pseudohypoaldosteronism), characterized by so-
dium chloride wasting, acidosis, hyperkalemia, and an elevated
24-hour urinary aldosterone excretion, occurs in infants only
[54, 55]. It is thought to he due to distal tubular unresponsive-
ness to circulating aldosterone, i.e., an end-organ thilure. This
syndrome seemed more prevalent in the past; recently it has
been reported only in Belgium (Proesmans W, personal commu-
nication). The defect is transient and disappears after age 2
years if the infant is adequately treated with sodium bicarbonate
and sodium chloride.
Subtype 5 (early childhood" type-4 RTA) is characterized
by hyperchloremic acidosis, hyperkalemia, and aciduria. Clini-
cal salt wasting does not occur and no azotemia or hypertension
is present. Unlike subtype 4, this subtype is thought to be due to
end-organ resistance to only two of the three aldosterone-
dependent functions of the distal tubule: potassium and hydro-
gen secretion are reduced, but sodium is reabsorbed normally.
This is the most common subtype of type-4 RTA and is found
with equal frequency in males and females; occasionally, sever-
al siblings are affected [22, 35—381. Characteristically, infants
and young children with this subtype are short or stunted, vomit
frequently, and fail to thrive.
Alkali therapy (4 to 20 mEq/kg/day of sodium bicarbonate)
entirely corrected the abnormalities in 13 children. Plasma
bicarbonate concentration became normal, and serum potassi-
um fell to  4.8 mEq/liter; growth accelerated and normal
height was achieved within 6 months of initiating adequate
alkali therapy [35—39]. Interestingly, after about 5 years of age,
alkali therapy was no longer needed. It is not known why
children with both subtype 4 and subtype 5 outgrow their
clinical manifestations. One can postulate that their initial
disorder represents an abnormal number or conformation of the
aldosterone receptors, possibly due to the short distal nephrons
characteristic of infants.
Patients with subtype 5 provide a unique opportunity to study
the pathophysiologic characteristics of the type-4 RTA hydro-
gen ion transport defect in a relatively pristine state: the patient
is free from the secondary effects of azotemia, clinical salt
wasting, and the major hormonal imbalance of subtypes I
through 4 [22, 35—381. We found that renal bicarbonate wasting
occurred during sustained correction of acidosis with high-dose
alkali therapy in each of 13 children despite consistently normal
or high values of both plasma renin and 24-hour urinary
aldosterone excretion. Further, in marked contrast to patients
with type-2 RTA, in whom bicarbonaturia is associated with a
marked increase in kaliuria, bicarbonaturia is not associated
with significant kaliuria (CK/Clfl 16%) in patients with sub-
type 5 of type-4 RTA. This observation supports the hypothesis
that distal tubular potassium secretion as well as hydrogen
secretion is defective in children with this subtype.
Two factors that affect renal stone formation in patients with
subtype 5 of type-4 RTA are worth noting: urinary calcium and
citrate excretion, As is widely known, both increased urinary
calcium excretion and decreased urinary citrate excretion pre-
dispose to renal stone formation. In the urine, citrate complexes
with calcium and increases its solubility, thereby decreasing
stone formation. Citrate also inhibits crystal formation and
growth in the urine. Presumably during chronic acidosis the
mobilization of bone buffers is increased, and in children with
type-I and -2 RTA, urinary calcium excretion rises during
acidosis [56—62]. In children with subtype 5 of type-4 RTA,
however, no rise in urinary calcium excretion during chronic
acidosis is found; thus, one might suspect that a relative
"hyperreabsorption" of calcium is present [35—391. In patients
with type-I RTA, all filtered citrate is reabsorbed during
acidosis because of the increased metabolic needs. in type-2
RTA, because of the associated proximal tubular defect, citrate
cannot be fully reabsorbed despite acidosis, and urinary citrate
excretion is high. A similar increase in urinary citrate excretion
occurs in subtype 5 of type-4 RTA. Thus, in untreated, chroni-
cally acidotic patients with subtype 5 of type-4 RTA, nephrocal-
cinosis probably does not occur because of calcium hyperreab-
sorption as well as the persistence of elevated urinary citrate
excretion.
Before we conclude our review of childhood RTA, I would
like to discuss briefly some of our recent studies on the long-
term effects of renal tubular acidosis.
A /0-year study of radiologic findings
A decade of radiographic findings in 92 patients with types-I.
-2 or -4 RTA (56 children and 36 adults) shows that bone disease
is rare in nonazotemic patients with RTA, and then only in
patients with type-2 RTA [63]. Nephrocalcinosis was radiologi-
cally demonstrable only in patients with type-l RTA but not in
children with type-I RTA who received "high-dose" alkali
therapy since infancy [22, 29, 30, 35, 36]; thus, acidosis and
subsequent decreased urinary citrate probably are predisposing
factors for nephrocalcinosis in type-I RTA [63].
Secondary effrcts of acidosis on growl/i and human growth
Iwiiao ne
Recent findings indicate that hyperchloremic acidosis alone
causes reversible, severe short stature and even stunting (height
 2.5 SD). in 10 children with nonazotemic type-l RTA,
acidosis caused short stature that was reversed when acidosis
was corrected with high doses of alkali [12, 13, 21]. Also, in 13
children with subtype 5 of type-4 RTA, short stature (mean
—2.4 SD) was corrected in 6 months with high-dose alkali
therapy [35—37, 64]. Because of these findings, we studied the
isolated effect of acidosis and its correction by alkali therapy on
hormonal and metabolic factors related to growth.
Human growth hormone (HGH) release was stimulated with
arginine and L-dopa infusion in 11 children with type-I RTA
and in 4 children with subtype S of type-4 RTA 165]. During
chronic acidosis (> 6 months, n = 7) and during acute,
experimentally induced acidosis (3 to 6 days, n = 15), peak
HGH release was blunted (< 8 ng/ml prepubertal, < 12 ng/ml
pubertal). Conversely, in individual paired studies, HGH re-
lease was normal following chronic (n = 15) or acute (n = 7)
correction of acidosis [65].
The results demonstrate that acidosis reduces peak HGH
release after standard stimulation tests in nonazotemic children
with types-I or -4 RTA and in normal children [65, 66]. The
study further suggests that plasma bicarbonate is a critical
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Fig. 2. Collagen synthesis: A schema (f the major steps (A) and the
final extraiellular enzy,na(ic step (B). The major part of the synthesis of
the collagen molecule is intracellular (A), but the critical final enzymatic
step that ensures normal strength and structural stability, through an
adequate cross-linkage of the collagen molecule, occurs extracellularly
(B) with the enzyme lysyl oxidase. The plasma activity of this collagen
synthetic enzyme, lysyl oxidase, is increased several fold during
hyperchloremic acidosis.
determinant of HGH release in children undergoing standard
HGH stimulation tests [65, 66].
Secondary eJfrcts of acidosis on collagen synthesis
The synthesis of collagen has seven major enzymatic steps,
the last of which is catalyzed by the extracellular enzyme lysyl
oxidase (LU) after the partially completed collagen molecule is
extruded from the fibroblast (see Fig. 2). In rats with experi-
mental hepatic fibrosis, and in chicks with vitamin D deficiency
(a syndrome in which acidosis and growth retardation are
chacacteristic), plasma LU activity is elevated. In 10 children
(ages 6 months to 18 years: 7 with type-I RTA, 3 with type-4
RTA), mean plasma LU activity was elevated eight- to tenfold
during acidosis. After correction of acidosis with alkali therapy,
the LU level immediately fell to normal [67—70]. In steady states
of at least one week duration, plasma LU activity correlated
inversely with plasma bicarbonate concentration over the range
of 15 to 23 mEq/liter (15 studies of 10 patients) [69, 701. In a 3-
year-old child with type-4 RTA (subtype 5), activity of LU was
measurable and was mildly but not markedly increased during
chronic, partially treated acidosis. But with complete withdraw-
al of alkali therapy for 4 days, LU increased fourfold; LU
activity then fell to unmeasurable levels within 24 hours of
institution of fully corrective alkali therapy [69]. This study
provided the first demonstration that acidosis directly affects
collagen metabolism.
Pseudoephedrine (Sudafed) excretion
Pseudoephedrine is a decongestant used commonly in the
pediatric population. The administration of pseudoephedrine
for chronic otitis for 6 weeks in a 6-year-old girl with type-I
RTA produced a weight loss of 6 pounds, an amphetamine-like
psychosis, and greatly elevated pseudoephedrine blood levels.
We postulated that the drug accumulated because her persist-
ently alkaline urinary pH favored the renal tubular reabsorption
of pseudoephedrine, which is a weak base (PKa = 9.4) [64, 71,
72]. The renal determinants of the urinary elimination of
pseudoephedrine were assessed in 15 studies in 8 subjects: 3
normal adults, 3 normal children, and one adult and one child
each with type-I RTA. The pseudoephedrine (5 mg/kg) was
administered orally; blood and urinary levels were measured
serially. Urinary pH was controlled at various levels by the
administration of sodium bicarbonate or ammonium chloride.
In all studies, 45% of the administered pseudoephedrine close
was excreted unaltered, and 6% 1.0% as norpseudofed.
Elimination half-life correlated significantly and directly with
the urinary pH [72]. Another factor determining pseudoephed-
rine excretion in an alkaline urine was urine flow rate [72].
These findings suggest that the elimination of pseudoephedrine
and its metabolite norpseudofed are importantly determined by
both urinary pH and urine flow rate in humans [72].
Questions and answers
DR. JOHN T. HARRINOTON: Could you tell us what the
precise pathophysiologic mechanism is for the renal bicarbon-
ate wasting in children and infants with type-l, i.e., distal,
RTA?
DR. MCSHERRY: Unfortunately, we don't really know the
precise proportion of bicarbonate reabsorption in proximal and
distal tubules in rapidly growing human infants and in children
of different ages. The GFR in normal infants (on a surface area
basis) is only about 50% that of older children and adults. One
of the speculations is that there is glomerular-tubular imbalance
for bicarbonate reabsorption during early infant development.
Ultimately, we are trying to account for the bicarbonate-
wasting phenomenon that occurs in children with type-I RTA
when their growth is two to three times normal, but which Ihen
disappears when their growth rate returns to normal. We
frequently observed children with type-I RTA who, with con-
tinued high-dose alkali, grow very rapidly in the first two years
of life, and then after they attain normal size, lose their renal
bicarbonate wasting. Another natural growth rate peak occurs
during normal adolescence, when the growth rate increases to
about 13 cm/year. We are anxious to see whether renal bicar-
bonate wasting returns at that time in these now normal-sized
children with type-l RTA in whom correction of acidosis has
been chronically sustained with alkali therapy.
DR. HARRINOTON: Have you analyzed bone biopsy speci-
mens in your patients? I am specifically interested in bone
carbonate levels.
DR. MCSHERRY: No, we have not done such studies in these
children.
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DR. JORDAN J. COHEN: It is well recognized, as you pointed
out, that the status of extracellular volume exerts an important
influence on proximal bicarbonate reabsorption. '['his prompts
me to ask two somewhat related questions. First, how much, if
any, of the bicarbonate wasting you observed during treatment
with large bicarbonate loads can he ascribed to the associated
expansion in extracellular fluid volume? Second, the practical
definition of bicarbonate wasting that you use, namely, the
excretion of 3 mEq/kg/day, must bear some relation to the
status of extracellular fluid volume. Does this value differ
significantly in accordance with the degree of volume expansion
induced by the bicarbonate titration protocol employed?
DR. MCSHERRY: First, renal bicarbonate wasting occurs in
our children with type-I RTA, even when plasma bicarbonate is
slightly or severely subnormal and even when no alkali therapy
is being given. Second, we have measured plasma volume in
several of these patients receiving alkali therapy, and plasma
volume never increases beyond normal limits despite the large
doses of alkali administration. Third. despite the continuous
high-dose alkali in these children, plasma aldosterone levels
tend to remain elevated or normal and plasma renins also
remain either high or normal. Therefore, we don't believe there
is any evidence to support the possibility that these large doses
of alkali are suppressing proximal bicarbonate reabsorption and
inducing iatrogenic bicarbonate wasting by volume expansion.
In contrast to our findings in children with type-I RTA, studies
show that when 10 mEq/kg/day of alkali is given to an otherwise
normal human, plasma renin activity and 24-hour urinary
aldosterone excretion are suppressed completely; the suppres-
sion occurs immediately and persists as long as the alkali load is
continued.
Your second question was why do we define renal bicarbon-
ate wasting as greater than or equal to 3 mEq/kg/day? Winters
and Kildeherg found in rapidly growing premature infants that
the maximum rate of endogenous acid production was 3 mEq/
kg/day. In children, this was due in large part to the rapid laying
down of new bone. Thus in growing children with RTA, only
when bicarbonaturia exceeds the upper limit of normal endoge-
nous acid production (3 mEq/kg/day) does it become the major
determinant of alkali therapy and thereby qualify for the term
"bicarbonate wasting."
DR. JEROME P. KASSIRER: Do you think that conversion of
type-I to type-4 RTA may be an iatrogenic artifact in some
instances? 1 am proposing that chronic ingestion of large
quantities of sodium bicarbonate could expand extracellular
volume and suppress renin and aldosterone. This phenomenon
is known to occur in normals [73], and it probably occurred in a
patient I have been following for more than 20 years. When I
first saw this woman, she had classic type-I R'I'A, and she
required only modest quantities of alkali to maintain normal
acid-base equilibrium. Some years later her bicarbonate re-
quirement increased, and with large alkali supplements, plasma
bicarbonate remained slightly below normal. Later, without an
alteration in renal function, she became hyperkalemic, and mild
hyperkalemia persisted even after we discontinued her potassi-
um supplements. The discovery that she had a suppressed
plasma aldosterone level at that time seemed to explain the
gradual conversion to a bicarbonate-wasting state. Have you
seen this sequence in children?
DR. MCSHERRY: We don't see conversion of type-I to type-4
RTA (or hyperkalemic, bicarbonate-wasting syndromes) in
these children. However, the time course of renal bicarbonate
wasting itself is a fascinating phenomenon in children with type-
I RTA. In infants growing as fast as 44 cm/year, major changes
take place in a few days that can take a year or so to occur in an
older child or adult. We have seen children who did not waste
bicarbonate when first treated (growing slowly), in whom larger
amounts of alkali therapy were required as time passed and
whose growth rate increased. The time frame in children is
much different, however, than in adults. Many children, initial-
ly well controlled on a low dose of alkali, need twice the dose of
alkali to maintain normal plasma bicarbonate concentration in 6
weeks or 2 months. Bicarbonate wasting continues in these
children until normal height is reached; then it abruptly stops.
In children this usually occurs 2 to 3 years after initiation of
therapy. As I just mentioned, we haven't watched enough
patients long enough to know whether bicarbonate wasting will
return during normal rapid growth in adolescence, If renal
bicarbonate wasting does return, I would anticipate that it might
stop after the adolescent growth rate falls from 15 cm/year to
zero.
DR. KASSIRER: Why do these children still have hyperaldo-
steronism if they are receiving adequate quantities of sodium
and alkali and are excreting it?
DR. MCSHERRY: Most of our children with type-I RTA on
chronic high-dose alkali have normal or only slightly elevated
levels of renin and aldosterone. We have 2 children (one of
them, the patient presented) who, despite large doses of alkali,
continue to have very high aldosterone and renin levels for
reasons not fully understood.
DR. KASSIRER: Does renal sodium wasting explain it?
DR. MCSHERRY: No. We have done sodium balance studies
in these patients using potassium bicarbonate as the only source
of alkali. 'l'he patients can conserve sodium normally (< 2 mEq/
day excretion in the urine) when dietary sodium intake is
severely curtailed (' 10 mEq/day). We questioned whether we
were chronically stimulating aldosterone secretion by continu-
ously administering potassium to these 2 hyperreninemic chil-
dren with type-I RTA who also have recurrent hypokalemia.
We therefore have continued to attempt to withdraw potassium
supplements hut have not been able to do so without causing
persistent hypokalemia. We have one adult with hereditary
type-I renal tubular acidosis—the only bicarbonate wasting
adult we have—who maintains a potassium ot' 1.7 mEq/liter
without potassium supplements. Because of the severe hypoka-
lemia we have never been able to withdraw her from potassium
therapy. This adult and our two children with type-I RTA (and
persistent potassium wasting and hyperaldosteronism) had their
disorders for a very long time before adequate alkali therapy
was started. We don't know whether the long duration of
acidosis and volume depletion allowed these patients to develop
some sort of secondary autonomous hyperaldosteronism.
DR. HARRTNOTON: You nientioned that despite bicarbonate
loading and induction of bicarhonaturia in your patients with
subtype 5 of type-4 RTA. there was no increase in urinary
potassium excretion. First, were the serum potassium levels
elevated in these patients? Second, what is your speculation as
to why there was no increase in potassium excretion? I would
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have suspected that an increase in distal bicarbonate delivery
might have caused an increase in urinary potassium excretion.
DR. MCSHERRY: In regard to your first question, serum
potassium levels do come down following the administration of
high-dose alkali therapy over a long period. During acute
bicarbonate infusion studies in these patients, fractional urinary
potassium excretion does not increase over the range of low to
normal plasma bicarbonate concentrations but remains low,
about 16%. Why urinary potassium excretion does not increase
during chronic alkali therapy in these patients is not well
known. The blood volume increases from low levels before to
normal levels after alkali treatment; I assume volume expansion
may have some role. Further, potassium may be driven intra-
cellularly with correction of acidosis. Unfortunately, no intra-
cellular potassium data are available in these patients. Finally,
during very rapid growth in children receiving constant diets,
more of the ingested sodium and potassium is incorporated in
new tissue and less is excreted in the urine then in the same
individual on a comparable diet during periods of slow growth.
DR. COHEN: what is the natural history of this form of RTA?
We don't see adult patients with this condition; I assume that
they get better.
DR. MCSHERRY: Children with subtype 4 of type-4 RTA (the
rare Cheek and Perry's disease described in the late l950s and
early l960s in Paris and England, and currently in Belgium)
have clinical salt wasting but "outgrow" the clinical expression
of their disease if they survive, and they appear normal in
adulthood. These patients have hyperkalemia, acidosis, and
clinical salt wasting; that is, all three distal tubular aldosterone-
dependent processes are defective. In our patients with "early
childhood," subtype 5 of type-4 RTA. salt wasting is not
present. The disease usually is manifested between 6.5 months
and 18 months o! age. In patients with other affected siblings,
we have diagnosed the defect during the first two weeks of life
but rarely see a spontaneous case that early. Usually these
patients outgrow their disorder at about 4 years of age if they
have received consistent, fully corrective alkali therapy. At that
time they appear to he completely normal, hut I suspect the
carrier state could he recognized in some way, perhaps if we
measured their urinary calcium or citrate excretion during
acidosis. The correction of the clinical syndrome of acidosis
that occurs in these older children who have grown well may
occur spontaneously because the proximal nephron takes over
more of the bicarbonate reabsorption (as it does in normal
children as they mature) and thus compensates for any slightly
defective function of the distal aldosterone-sensitive nephron.
The other possibility is that maturation in capacity or function
of distal tubule aldosterone receptors occurs.
DR. HARRING1ors: The studies you have presented concern
alterations and stimulation of growth in nonazotemic renal
acidosis and not in azotemic renal acidosis. Given your impres-
sive results in stimulating growth, it seems appropriate that this
notion be extended to azotemic renal acidosis. Admittedly,
there are probably many other reasons for growth retardation in
children with azotemic acidosis. Have you tried to fully and
totally correct acidosis in children with chronic renal failure to
see whether growth is affected?
DR. MCSHIRRY: lam not aware of studies that have carefully
evaluated growth in azotemic children whose acidosis is fully
corrected with sodium bicarbonate. Drs. Portale, Booth, Tsai,
and Morris are investigating the effect of vitamin D metabolites
in children with moderate chronic renal failure, but that work is
preliminary 1741. With vitamin D deficiency alone, an acidosis
develops that reverses with repletion of vitamin [). The changes
in acid-base status induced by the vitamin D metabolites alone
cause problems in the interpretations of studies of growth in
azotemia. Nevertheless, these studies on vitamin D are the one
area in which growth during azotemic acidosis is currently
being investigated.
DR. MARK MOLITCH (Endocrinology Division, NEMC): Is
the acidosis that arises in vitamin D delIciency due directly to
the vitamin D deficiency or due to secondary hyperpara-
thyroidism?
DR. MCSHERRY: We have looked at adults with sprue and
children with type-2 renal tubular acidosis; both have apparent
vitamin D deliciency and secondary hyperparathyroidism. in
both, the secondary hyperparathyroidism and acidosis can he
rapidly corrected to some degree by calcium infusions that
inhibit parathyroid hormone. Chronically in patients with
sprue, both normocalcemia and vitamin D replenishment ap-
pear necessary to reverse the type-2 RTA and Fanconi syn-
drome.
DR. HARRJNGTON: Are the differences in growth hormone
that you showed clinically significant, and would they he
anticipated to lead to changes in linear growth?
DR. MCSHERRY: Yes, in pituitary dwarfs with either isolated
growth hormone deficiency or panhypopituitarism, peak las-
ma human growth hormone level is usually less than 2 ng/ml.
Patients with slow growth due to isolated partial growth hor-
mone deficiency are called "blunted growth hormone respond-
ers." Peak HGH levels range between 2 and 8 ng/ml in
prepubertal patients and from 2 to IS ng/ml in pubertal patients.
When these slowly growing but otherwise normal patients
("blunted responders") are given growth hormone, they grow
normally. Thus, the low levels of HGH found in children with
RTA when acidotic certainly are in the clinically significant
range.
DR. MotlicH: Have you been able to correlate somatomedin
levels with growth?
DR. MCSHLRRY: if we could measure somatomedin with
confidence, we could evaluate its role in the growth retardation
of hyperchloremic acidosis. There have been a numbe]r of
problems with somatomedin measurement. With new, more
reliable assays, we soon will measure somatomedin-c in sam-
ples we have saved, but we have no data at present.
DR. KASSIRER: How do ou explain the remarkable elevation
of plasma bicarbonate on admission to UCSF in this patient
with type-i RTA with renal bicarbonate wasting? Were you
attributing it all to treatment with chlorothiazide?
DR. MCSHERRY: No. Some patients with type-I RTA, espe-
cially adults, have severe alkalosis with potassium depletion
alone. This patient was not only volume depleted because of
chlorothiazide therapy, but also had vomiting and severe pctas-
sium depletion to account for her alkalosis.
DR. KASSIRER: I'm not entirely satisfied with that explana-
tion. I wonder whether selective depletion of chloride coupled
with sodium avidity could be playing a role, at least in maintain-
ing the alkalosis. Why these patients become severely alkalotic
808 Nephro/og' Forum
in the first place is more obscure, but I wouldn't be surprised to
find that the history in many children would disclose that they
had been vomiting. Extremely severe metabolic alkalosis al-
most always results from external loss of hydrochloric acid
from the stomach.
DR. MCSHERRY: Although this child had vomiting through-
out, as I said before, many of our adults with type-I RTA
presenting with alkalosis have only hypokalemia to account for
their alkalosis.
Da. COHEN: In view of the experimental evidence that a
reduction in carbon dioxide tension may have an independent
effect on renal bicarbonate reabsorption and contribute to the
hypobicarbonatemia of chronic metabolic acidosis 175], I am
curious to know whether the level of secondary hypocapnia in
youngsters with RTA is similar to that observed in other forms
of acidosis of comparable severity.
DR. MCSHERRY: I know of no directly comparative study of
that nature in children with RTA. With severe chronic acidosis,
the carbon dioxide tension in children with type-l RTA usually
is 18 to 20 mm Hg. This reduction appears to be comparable to
that in patients with diabetic ketoacidosis, for example.
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